Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
<p>Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer...</p>
Read original article ↗
Related Articles
Barbara Mazzolai Wants to Build a New Field of Robotics
Throughout her career, roboticist Barbara Mazzolai has turned to nature for inspiration. Now she wants to ensure the tec
SuperCom Expands into 21st New U.S. State with New Electronic Monitoring Contract in Indiana
Community Corrections Agency Selects SuperCom's PureOne GPS Solution Following Field Evaluation for Adult and Juvenile P
These discreet hearing aid glasses now have better voice boosting and battery life
EssilorLuxottica, the company that Meta partnered with for its Ray-Ban smart glasses, announced a new version of its Nua
WOODCLIFF LAKE, N.J., Sept. 22, 2026 /PRNewswire/ -- Powerfleet, Inc. (Nasdaq: AIOT) (JSE: PWR), a global leader in the